{"id":652614,"date":"2023-05-23T20:26:01","date_gmt":"2023-05-23T20:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=652614"},"modified":"2023-05-23T20:26:01","modified_gmt":"2023-05-23T20:26:01","slug":"meconium-aspiration-syndrome-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-key-companies-fervent-pharmaceuticals-astellas-pharmaceuticals-bayer-pfi","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/meconium-aspiration-syndrome-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-key-companies-fervent-pharmaceuticals-astellas-pharmaceuticals-bayer-pfi_652614.html","title":{"rendered":"Meconium Aspiration Syndrome Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)| Key Companies – Fervent Pharmaceuticals, Astellas Pharmaceuticals, Bayer, Pfi"},"content":{"rendered":"
\n
\"Meconium<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Meconium Aspiration Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Meconium Aspiration Syndrome, historical and forecasted epidemiology as well as the Meconium Aspiration Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Meconium Aspiration Syndrome Market Insights, Epidemiology, and Market Forecast-2032<\/a>” report delivers an in-depth understanding of the Meconium Aspiration Syndrome, historical and forecasted epidemiology as well as the Meconium Aspiration Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n

Meconium Aspiration Syndrome Overview<\/strong><\/p>\n

Meconium aspiration syndrome occurs when a newborn breathes a mixture of meconium and amniotic fluid into the lungs around the time of delivery. Meconium aspiration syndrome, a leading cause of severe illness and death in the newborn, occurs in about 5 percent to 10 percent of births.<\/p>\n

\"\"<\/p>\n

Meconium Aspiration Syndrome Epidemiology Insights<\/strong><\/p>\n

In the industrialized world, meconium in the amniotic fluid can be detected in 8-25% of all births after 34 weeks gestation. Historically, approximately 10% of newborns born through meconium-stained amniotic fluid developed meconium aspiration syndrome.<\/p>\n

 Higher risk of MASINT was noted at advanced gestation, with 34% of cases born beyond 40 weeks, compared with 16% of infants without MAS. Fetal distress requiring obstetric intervention was noted in 51% of cases, and 42% were delivered by cesarean section.<\/p>\n

Click here to learn more about the Meconium Aspiration Syndrome Market Landscape<\/a><\/strong><\/p>\n

The Report Covers the Meconium Aspiration Syndrome Epidemiology Segmented by:<\/strong><\/p>\n